Short answer
Rezolute, Inc. (RZLT) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$16M
- +14.5% YoY · +29.0% QoQ
- EPS (diluted)
- −$0.15
- +44.4% YoY · +31.8% QoQ
Source: XBRL data from the Rezolute, Inc. (RZLT) Q1 2026 10-Q on SEC EDGAR. USD.
Rezolute, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, no meaningful revenue since inception in March 2010
- Profitability: operating losses expected for foreseeable future; no margin percentage disclosed
- Best-performing program: tumor HI EAP, 75% of IV dextrose/TPN patients achieved complete discontinuation
- Workforce reduced by 29 employees; $1.5M severance expense in fiscal Q2 2026
- Near-term outlook: upLIFT enrollment and topline results expected in second half of 2026; FDA sunRIZE update also expected then
Risk Factors
- New clinical-trial risk: FDA-permitted upLIFT design modifications may fail to demonstrate efficacy or meet endpoints
- Regulatory risk: FDA may reject additional sunRIZE datasets as inadequate for approval, efficacy, or commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rezolute, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.